StockpollyBeta
Get App
Popularity #1,278
AMLX · NASDAQ · Biotechnology

Amylyx Pharmaceuticals (AMLX)

Developing avexitide-led therapies for endocrine and neurodegenerative diseases.

$32.99
vs last close+0.60 (+1.85%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue10310889−10−1000000
Cost of revenue5911681022020000
Gross profit9799−28−90−1−220−20000
799794457540164316364446
Research & development304537232123222720212824
495258221817161616151622
General & administrative00000016000022
Other expenses0000360−220−20000
Operating income192−122−53−76−41−38−43−36−37−44−46
454−1932212422
Interest income444432222332
Other non-operating income0−5−419−3−2−2−1−2−6−2−2
Income before tax226−119−73−73−38−36−41−34−33−41−43
Income tax expense22000−1000000
Net income from continuing operations215−119−73−73−38−36−41−34−33−41−43
Net income215−119−73−73−38−36−41−34−33−41−43
EPS, basic$0.31$0.07−$1.75−$1.07−$1.07−$0.55−$0.42−$0.46−$0.37−$0.28−$0.37−$0.39
EPS, diluted$0.30$0.07−$1.75−$1.07−$1.07−$0.55−$0.42−$0.46−$0.37−$0.28−$0.37−$0.39
Weighted average shares, basic67676868686986899395111111
Weighted average shares, diluted70696868686986899395111111
EBITDA197−118−72−72−38−36−41−34−31−41−43
Depreciation & amortization000000000000
EBIT196−119−73−73−38−36−41−34−31−41−43